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Non-alcoholic fatty liver disease (NAFLD) represents a global healthcare chal-
lenge, affecting 1 in 4 adults, and death rates are predicted to rise inexorably.
The progressive form of NAFLD, non-alcoholic steatohepatitis (NASH), can lead
to fibrosis, cirrhosis, and hepatocellular carcinoma. However, no medical treat-
ments are licensed for NAFLD-NASH. Identifying efficacious therapies has been
hindered by the complexity of disease pathogenesis, a paucity of predictive pre-
clinical models and inadequate validation of pharmacological targets in humans.
The development of clinically relevant in vitro models of the disease will pave
the way to overcome these challenges. Currently, the combined application of
emerging technologies (e.g., organ-on-a-chip/microphysiological systems) and
control engineering approaches promises to unravel NAFLD biology and deliver
tractable treatment candidates. In this review, we will describe advances in pre-
clinical models for NAFLD-NASH, the recent introduction of novel technologies in
this space, and their importance for drug discovery endeavors in the future.
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, mainly affecting pa-
tients with obesity and type 2 diabetes mellitus (T2DM). NAFLD is the umbrella-term used for a range of
conditions caused by a build-up of fat in the liver and encompasses isolated fatty liver (steatosis) and
non-alcoholic steatohepatitis (NASH) with increasing degrees of liver inflammation, fibrosis (scarring),
and potentially cirrhosis (end-stage fibrosis with vascular changes and functional impairment). Its world-
wide prevalence is currently 25%, with 41% of the patients ultimately developing fibrosis (Younossi
et al., 2016) and is projected to increase further by up to 18.3% in some developed countries by 2030 (Estes
et al., 2018). Sedentary lifestyles and booming economic growth in the most developed countries sustain
such trends, which see NASH becoming the leading cause of liver transplant (Zou et al., 2020).
To date, there are no licensed pharmacological treatments for NASH. While bariatric surgery is effective in
a small proportion of patients (Lee et al., 2019), diet and exercise remain the cornerstone of disease man-
agement, due to evidence that a 10% body weight loss allows a reversion of steatosis, inflammation, and
even fibrosis (Vilar-Gomez et al., 2015). However, the difficulty of achieving and sustaining this supports the
need for disease-specific pharmacological treatment. Current medical treatment also comprises drugs for
comorbidities related to NAFLD. Patients with or without T2DMmay be treated with anti-diabetic medica-
tions. A recent systematic review of 18 trials (Blazina and Selph, 2019) presented evidence that supports the
efficacy of some diabetes drugs in reducing liver fat and resolving NASH (e.g., pioglitazone, liraglutide),
although associated weight gain with pioglitazone warrants caution. Blazina and Selph (2019) concluded
that larger trials are needed to elucidate the benefits and risks of diabetes pharmacotherapy in NAFLD
patients.
Given the complexity of NAFLD pathophysiology and the phenotypic heterogeneity, both genetic and
environmental factors are thought to contribute to disease progression and susceptibility (Eslam et al.,
2018). Several genes that participate in lipid droplet remodeling, hepatic very low density (VLDL) secretion
and generation of predominant molecular species of phosphatidylinositol (PI) in cell membranes have been
identified as NAFLD genetic variants. Specifically, the most well-described variants are patatin-like phos-
pholipase domain-containing protein 3 (PNPLA3) I148M (Romeo et al., 2008), transmembrane 6 superfamilyiScience 25, 103549, January 21, 2022 ª 2021 The Author(s).





Reviewmember 2 (TM6SF2) E167K (Kozlitina et al., 2014) and obesity-linked suppression of membrane-bound O-
acyltransferase 7 (MBOAT7) (Mancina et al., 2016). The PNPLA3I148M variant has been linked to NASH pro-
gression and fibrosis (Valenti et al., 2010; Rotman et al., 2010; Sookoian et al., 2009) and replicated in several
independent genome-wide association studies.
Increasingly, it is suggested that a ‘one size fits all’ approach to treat NAFLDmight not be optimal given the
heterogeneity of the disease. Moreover, early pathways that participate in NAFLD progression are not
commonly investigated in clinical trials, as the predominant focus is on NASH with moderate-to-severe
fibrosis or cirrhosis. A comprehensive understanding of the whole disease spectrum –and not just the later
stages– could be the key to understanding this disease and its progression.
Ahead of clinical trials, in vivomodels remain a crucial tool to studyNAFLD. Larger animalmodels such as rabbits
(Ogawa et al., 2010), monkeys (Hansen et al., 2017) or minipigs (Pedersen et al., 2020; Lee et al., 2009) may have
greater proximity to humans but can present ethical issues, are more difficult to handle and can be time-
consuming and costly. While relying mostly on rodents, in vivomodeling has shown improved human translat-
ability in studies of NAFLD pathogenesis and evaluation of potential therapeutic targets (Hansen et al., 2020;
Clapper et al., 2013). However, rodent models also have disadvantages. Indeed, the human relevance and pre-
dictivity of laboratory mice is limited by species-specific biology and genetics (Reimer et al., 2020), coupled with
physiological factors that result from growth in the laboratory, as opposed to a natural environment. Critically,
this can affect the microbiome of mice and their potential response to drug therapies that are subsequently
funneled through to human trials (Rosshart et al., 2019). Of note, the microbiome has been strongly linked to
NAFLD pathogenesis (described in more detail in the following section).
In vitro models are, in many settings, a suitable alternative for studying NAFLD, as a result of increasing
sophistication and the ability to recapitulate several hallmarks of the disease. A multi-disciplinary approach
to the development of in vitro models led to solutions far more complex than the traditional two-dimen-
sional (2D) cultures (e.g., liver-on-a-chip platforms and three-dimensional (3D) models). While supporting
a better understanding of the disease, these models could be used as reliable drug screening platforms. In
this review, we will detail which in vitro models have been used to date for NAFLD and NASH, discussing
their advantages and disadvantages. We offer our perspective on future developments and translational
opportunities in this field, which will be of relevance to researchers interested in the pathophysiology of
NAFLD, drug development, and bioengineering.NAFLD PATHOGENESIS
A detailed discussion of NAFLD pathogenesis is beyond the scope of this article; the interested reader is
directed to recent comprehensive reviews (Loomba et al., 2021; Cariou et al., 2021). The current model of
NAFLD-NASH pathogenesis is one of ‘substrate overload’, whereby the liver’s capacity to handle the pri-
mary metabolic energy substrates (e.g., carbohydrates and fatty acids) is overwhelmed, leading to the
accumulation of toxic lipid species.
Initially, the expansion of the subcutaneous adipose tissue in obese NAFLD patients leads to the accumu-
lation of free fatty acids (FFA) in the muscles. This induces insulin resistance (IR), inhibiting glucose uptake
(Brunt et al., 2015; Godoy-Matos et al., 2020). Concurrently, IR also compromises fat storage in adipocytes,
causing FFA to be released into circulation and reaching the liver. Here, FFA induces hepatic IR, gluconeo-
genesis, very low-density lipoprotein (VLDL) release, as well as an increase of pro-inflammatory adipokines.
To balance the elevated blood glucose levels, insulin, and FFA, the liver increases the storage of fatty acids
and their synthesis through de novo lipogenesis, regulated by the sterol regulatory element binding pro-
tein-1 (SREBP1c) (Donnelly et al., 2005). Some sphingolipids, besides being correlated with IR, are also
linked to hepatic oxidative stress and inflammation, suggesting their importance in NASH progression
(Apostolopoulou et al., 2018).
The major difference between NAFLD and NASH is the presence of hepatocellular injury. In NASH, there is
an increase of reactive oxygen species (ROS) andmitochondrial uncoupling, as a consequence of the meta-
bolism of the fatty acids present in hepatocytes (Brunt et al., 2015). Hepatocyte ballooning (a special form of
liver cell degeneration) has also been linked to the progression of NAFLD. These large cells with irregular
cytoplasm show diminished expression of caspase-9 (conferring resistance to apoptosis) and enhanced




Reviewfibrogenesis (Hirsova andGores, 2015). Kupffer cells (KC) and infiltratingmacrophages contribute to hepat-
ic inflammation, caused by the accumulation of fatty acids or damage-associated molecular patterns
(DAMPs) released by the dying hepatocytes. They can activate toll-like receptors (TLRs) and the inflamma-
some, maintaining the inflammatory environment; and promote fibrosis through the activation of hepatic
stellate cells (HSC). These cells play a critical role in fibrosis, and perpetuate inflammatory activity in the liver
by increasing ROS and CCR5 levels, leading to extracellular matrix (ECM) deposition through stimulation
by transforming growth factor b (TGFb) (Pafili and Roden, 2020).
Gut microbiota dysbiosis (an ‘‘imbalance’’ in the gut microbial community) is also believed to play an
important role in disease progression, as suggested by the distinctive microbiome signatures of NAFLD
patients. Bacteria and their products, which reach the circulation and liver as the tight junctions of the in-
testinal barrier weaken, can trigger tissue and systemic inflammation. Some of these bacteria can release
ethanol-like products, increasing ROS levels and inflammation, and hence promote NASH progression
(Chen and Vitetta, 2020).
Although disease progression is variable in NAFLD,5% will progress to cirrhosis, with an increased risk of
hepatic decompensation, hepatocellular carcinoma (HCC), and liver-related mortality (Lindenmeyer and
McCullough, 2018). Interestingly, HCC in NAFLD patients may also arise in non-cirrhotic liver (Huang
et al., 2021). In a recent meta-analysis, non-cirrhotic NASH subjects were at greater risk of developing
HCC than non-cirrhotic patients of other etiologies of liver disease (odds ratio 2.61) (Stine et al., 2018).
IN VITRO CULTURE SYSTEMS IN NAFLD
Cell lines
Cell lines arewidely used in research anddrugdevelopment.When compared to in vivomodels, cell lines canbe
easily cultured at large scale in a cost-efficientmanner. Furthermore, they can bemaintained longer than current
NAFLD ex vivo models, which have a usual life-span of 5–15 days (Wu et al., 2018; Palma et al., 2019).
According to their origin, cell lines are either tumor-derived (commonly known as immortalized), primary cell lines,
or pluripotent stem cells (PSC). Immortalized cell lines used for NAFLD research (e.g., HepaRG, THP-1 or LX-2),
offering unlimited growth and stable phenotype, streamline standardized culture protocols and assay reproduc-
ibility (Ramboer et al., 2014). Nonetheless, mutations in immortalized cell lines can hamper translation of observa-
tions to the human in vivo condition; for instance, HepG2 is characterized by the PNPLA3 I148Mmutation, which is
known to affect somemetabolic functions (Gunn et al., 2017). Primary human cells, isolated from liver tissue as he-
patocytes or non-parenchymal cells (NPC), better resemble the in vivo phenotype (Wilkening et al., 2003). Indeed,
harvesting of these cells from NAFLD patients enhanced the accuracy of drug metabolism studies (Ganji et al.,
2015; Schwartz et al., 2020). However, their limited culture time and availability, especially for non-pathological
(‘‘healthy’’) controls, as well as sample heterogeneity, are disadvantages (Zeilinger et al., 2016; Bell et al., 2018).
When focusing on NAFLD modeling, inherent donor liver variability represents a double-edge sword, setting
the basis for the investigation of genetic polymorphisms (Müller and Sturla, 2019). Lastly, PSC canbedifferentiated
into liver-like cells from liver stem cells, induced pluripotent stem cells (iPSC) or embryonic pluripotent stem cells
(ESC) (Hu and Li, 2015; Touboul et al., 2010; Takahashi et al., 2007). Cell differentiation, achieved via addition of
growth factors and nutrients to the culturemedium, results in phenotypic similarity to primary cell lines in addition
to indefinite expansion in culture (Soret et al., 2021). Moreover, iPSC are the preferred PSC for investigation, the
use of ESC being associated with ethical concerns (Zeilinger et al., 2016). Recent in vitromodels with human PSC
have been developed by Sinton et al. (2021); Holmgren et al. (2020); Coll et al. (2018) for NAFLD modeling. In
Table 1, advantages and disadvantages of various cell lines used in NAFLD in vitro modeling are detailed.
Cell culture models
2D and 3D cultures have been extensively used in NAFLD research and in vitro modeling (Figure 1, Table
S1), albeit to a different extent. We have performed a systematic review to observe the evolution and
focus of in vitro models in NAFLD (Figure S1). Our systematic review indicated that researchers predom-
inantly favored 2D monocultures (59.4%) to more complex models (2D co-cultures (14%), spheroids
(9.7%), organoids (7.3%), liver-on-a-chip (7.8%), collagen gel sandwiches (1.2%), and micropatterned cul-
tures (0.6%). When analyzing the selection of cell culture systems over time (Figure S2), we observed an
increasing trend in the publication of 3D in vitro models, specifically in on-chip cultures. This suggests 3D
culture systems are becoming more relevant in this field. Focusing on the large number of publications in
monocultures in 2020, we note that these systems have been used in conjunction with additional in vivoiScience 25, 103549, January 21, 2022 3
Table 1. In vitro cell lines that have been used to investigate NAFLD, highlighting their advantages and disadvantages





– Easy to maintain
– Uptake and storage of
exogenous FA












– Low FA oxidation
– PNPLA3 I148M
mutation
– Mainly LDL secretion
Green et al. (2015, 2020); Gunn et al.
(2017); Jennen et al. (2010); L}orincz




– Closer phenotype to
human hepatocytes
– Growth on glucose
deficient medium
– In liver spheroids,
high sensitivity to drug-
induced liver injury
– Strong contact inhibition
of growth







– Low basal expression
of CYP2E1
Baquerizo et al. (2015); Flynn and
Ferguson (2008); Garcia et al. (2011);






– Expression of several
CYP and phase II enzymes
– Uptake and storage of
exogenous FA
– Secretion of lipoproteins
– No PNPLA3 mutation






– No bile collection
German and Madihally (2019);
Green et al. (2020); Jennen et al.
(2010); L}orincz et al. (2021)





– Fetal phenotype Hu et al. (2013)
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Wu et al. (1994)
Hepa1-6 Mouse carcinoma
cell line












– Easy expansion in
culture
– High efficiency for
DNA transfection







Hartley et al. (2008); Taciak et al. (2018)
THP-1 Human monocytic
cell line
– High growth rate
– High reproducibility










(until passage no. 25)
– Differences with
human phenotype
Chanput et al. (2014)













































Cell line Description Advantages Disadvantages References
































Vande Bovenkamp et al. (2007);
Weiskirchen et al. (2013); Xu et al.
(2005)
T6 stellate cells Rat primary HSCs
















Van de Bovenkamp et al. (2007); Vogel




















– Lose proliferation in
long-term
– Difficult reproducibility
Brandon et al. (2003); Green et al.
(2020); Wilkening et al. (2003)
3T3-L1 MBX Mouse fibroblast – Adipocyte differentiation
– Robust response to insulin
– Present lipid droplets
– Low proliferation rate ATCC; Berger and Géloën (2019)













































Cell line Description Advantages Disadvantages References
3T3-J2 Embryonic mouse
fibroblast
– Expression of genes present
in liver
– Use in multicellular aggre
gates to enhance liver
functions
– Stabilisation of liver pheno






Bhatia et al. (1998); Ware et al. (2021)
Liver sinusoi
dal endothelial cells (LSEC)
Primary human cell
line







– Rapid loss of
differentiation
German and Madihally (2019);
Poisson et al. (2017)




– Generation of vascular-
like endothelial network when
cultured with hepatocytes in
spheroids
– Easy access
– Established protocols for
tissue culture in a serum-free
medium
– Non-liver source




when co-cultured with HepaRG
than LSEC
German andMadihally (2019); Medina-
Leyte et al. (2020)
Caco-2 Human epithelial cells from colorectal
adenocarcinoma
– Spontaneous change in entero-
cytic characteristics at confluence
– Tight junctions between cells
– Genotypic and phenotypic drifts
due to repeated passaging
– Presence of multilayer zones
Briske-Anderson et al. (1997); Poncede
León-Rodrı́guez et al. (2019)
NCTC-1469 Mouse NPC from liver cell line – Expression of estrogen receptors Asahi et al. (2010)
Pluripotent stem cells (PSC) Stem cells that can differentiate into
endoderm, mesoderm or ectoderm
– Differentiation into desired cell
type
– Similar phenotype to primary cell
lines
– Unlimited culture time
– Fetal phenotype
– No standardized differentiation
protocol
– Epigenetic memory may prevent
differentiation
– Differentiation is time consuming
– Cost












































Figure 1. Cell sources and in vitro models used in NAFLD studies
Primary human hepatocytes (PHH), primary non-parenchymal cells (PNPC), stem cells and tumor-derived cell lines
(cyan panel) can all be used to create two-dimensional (2D) and three-dimensional (3D) models for NAFLD (pink panel).
2D cultures (e.g., monocultures and co-culture) are denoted by a single or several cell types growing in a monolayer. 3D
cultures (e.g., collagen gel sandwich, spheroids, organoids or liver-on-a-chip) have been recently introduced to elucidate
NAFLD, and their development can rely on bio-printing technology. Self-aggregated spheroids present an accumulation
of carbon dioxide (CO2) and waste in their core. Cell culture models are listed by increasing cost, longevity and
complexity. While complexity correlates with ability of the model to accurately capture the disease phenotype, simpler




Reviewexperiments, or as a benchmark for more sophisticated in vitro models. As an example, the insert in Fig-
ure S2 distinguishes publications in 2020 that have used monocultures as the only in vitro experiment
from those that used them in combination with other cell culture models. We speculate that technolog-
ical advances, standardizing the development of more complex and affordable solutions, might underlie
this observation.
As reported above, 2D monoculture is the most established NAFLD in vitromodel. In this system, steatosis
induction is routinely performed by adding a mixture of unsaturated and saturated FFA to the culture me-
dium. Typically, oleic acid (OA) and palmitic acid (PA) are selected, being the most abundant in humans
(Hodson et al., 2008). According to our systematic search the most commonly used ratio for these FFA is
1:2 (PA:OA). This FFA ratio exposure emulates dietary conditions that are commonly observed in vivo,
inducing hallmarks of NAFLD-NASH (e.g., cytoplasmic accumulation of TG in hepatocytes, ER stress,
inflammation, and cell death) (Gomez-Lechon et al., 2007).
The low cost, ease of use, and suitability for high-throughput screening make 2D monocultures attractive
for disease modeling. Here, the choice of cell sources constrains the NAFLD mechanistic studies enabled
by the in vitromodel. For example, Lyall et al. (2018) showed that hepatocyte-like cells derived from human
ESC retained the ability to form the cytosine modification 5-hydroxy-methylcytosine (5hmC), rapidly lost
when culturing HepG2, providing ameans to elucidate the role of epigenetic dysregulation in NAFLD path-
ogenesis. Similarly, an hPSC-derivedmodel was used to study the re-wiring of mitochondrial metabolism in
early steatosis (Sinton et al., 2021). Monoculture models for NAFLD have also been valuable for investi-
gating metabolic and fibrotic pathways (Graffmann et al., 2016; Kanda et al., 2018; Zhang et al., 2016), eval-
uating therapeutic compounds (Boeckmans et al., 2020; Armstrong et al., 2016; Anfuso et al., 2020), and
assessing hepatic drug metabolism/toxicity (Gomez-Lechon et al., 2003).
Notwithstanding the advantages outlined above, 2D monocultures are unable to faithfully mimic in vivo
NAFLD conditions due to the lack of interaction with NPC and disturbances in the extracellular environ-
ment. An improvement over this system is provided by 2D co-cultures, typically involving two cell types,
such as hepatocytes and NPC, growing in a monolayer. As with monocultures, the steatotic phenotype
can be induced upon treatment with FFA. Interestingly, a co-culture of Huh7 and LX-2 enabled Barbero-
Becerra et al. (2015) to demonstrate the key role of hepatocyte-HSC crosstalk in the activation of HSC, a
key feature of NASH. Co-cultures including macrophages (Zhong et al., 2017; Chen and Ma, 2019) have
also elucidated the role of multiple inflammatory pathways in NAFLD and NASH.8 iScience 25, 103549, January 21, 2022
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Figure 2. Systematic analysis of the scientific literature on NAFLD in vitro cell culture models published between 2007 and 2021
(A) Trend over time of scientific publications centered on NAFLD in vitro models, clustered by application. Despite the majority published studies using
in vitromodels focused on NAFLD biology (orange), the past years have seen a marked increase in scientific articles presenting novel in vitromodels (purple)
or using available culture systems for compound testing (cyan). The concurrent decrease in investigations of the role of specific pathways and/or proteins in
NAFLD pathogenesis suggests a shift in focus and efforts within the scientific community.
(B) Barplot showing the percentage of in vitro models that have been used to study steatosis, inflammation, fibrosis, or hepatocellular ballooning. For each
disease hallmark, publications are clustered, according to their focus, in NAFLD (cyan), NASH (blue) or both NAFLD and NASH (dark blue). Steatosis is the
most studied feature in NAFLD and NASH, followed by inflammation and fibrosis. Hepatocellular ballooning is the least studied feature in the scientific
literature. For more information regarding the historical perspective of the evolution of in vitro models for NAFLD.




ReviewNAFLD andNASH can be induced in 2D co-cultures of PHH and iPSC (Parafati et al., 2018), yet their capacity
as accurate in vitro models decays with time as they lose their xenobiotic metabolism and hormone
response (Gurevich et al., 2020). 3D cultures can enhance these features, allow cell-cell interactions and
cell polarity (Treyer and Müsch, 2013; Godoy et al., 2013). They can provide new insights into complex
physiological mechanisms and potential therapeutic targets, increasing our knowledge of NAFLD. Further-
more, they represent a suitable alternative to in vivo models at early stages of drug development (Ro-
mualdo et al., 2021; Beisner et al., 2021; Eilenberger et al., 2020). The main 3D in vitro models used for
NAFLD –spheroids, organoids, and microfluidic devices– are detailed in the following section.
We classified the NAFLD in vitro models identified in our systematic search, according to their intended
application, into NAFLD biology studies and compound testing. 47.9% of the publications relied on
in vitro models to elucidate the role of different proteins, pathways or hallmarks of the disease; 18.8% of
the papers detailed the development of new in vitro models to better mimic NAFLD biology and its pro-
gression; while 33.3% of the studies assessed the therapeutic potential of putative compounds and drug
targets for NAFLD and NASH.
Despite a larger number of studies focused on the biology of NAFLD, the last 3 years have seen an increase
in publications reporting compound testing (Figure 2A). This, together with the simultaneous decline in the
study of disease mechanisms in NAFLD, suggests a possible shift in research on the condition. Specifically,
recent publications leverage available knowledge on NAFLD pathogenesis to devise strategies for treat-
ment. We explored whether this shift in the field was promoted by a greater involvement of pharma, but
did not observe any direct link, as most of the investigations remain hosted in academic settings. We
also noted that despite the divergence in their severity and risk of progression, comparable effort has
been devoted to NAFLD (51.4% of the studies) and NASH (43.7%). Only 4.9% of the investigations pro-
posed in vitro models to mimic both conditions. Considering the varied clinical outcomes within the dis-
ease spectrum, it would be preferable to consider both NAFLD and NASH when investigating the disease.
This is of paramount importance for compound testing since the mechanism of action (and potential effi-
cacy) of drugs will depend on the disease stage.
In Figure 2B the distribution of the hallmarks of NAFLD/NASH across the studies is reported. Most publi-




Reviewby the predominant use of monocultures of hepatocytes. Interestingly, hepatocellular ballooning has
barely been explored in these studies. Although it is difficult to objectively measure the presence of bal-
looned hepatocytes in patients’ biopsies (Kakisaka et al., 2018), they are a pathognomonic histological
feature of NASH that should be considered when studying this disease.
3D TISSUE CULTURE MODELS IN NAFLD
Three-dimensional cultures are emerging as a bridge between the easy-to-use 2D cell cultures and more
complex in vivo models. By maintaining hepatic cell types within a controlled microenvironment, 3D liver
models better mimic the in vivo organ phenotype. From spheroids composed of a single cell type to multi-
cellular aggregates includingNPC and immune cells, 3D cultures canmodel the liver organotypic structure,
retaining paracrine cell-cell interactions and metabolic functions for several weeks. Moreover, these
models can be used to study fluid flow and perfusion when cultured on a chip. In this section, we will review
the 3D culture models most recently proposed to recapitulate NAFLD. Specifically, we will detail the latest
developments in spheroids, organoids, liver-on-a-chip and bio-printed platforms.
The collagen gel sandwich has been extensively used to culture liver cells (Engl et al., 2004; Sandwich, 2006;
Kono et al., 1997; Choi and Choi, 2013; Wang et al., 2004). In this model, hepatocytes are seeded between
two layers of collagen gel. The obtained structure better resembles the in vivo conditions, as demonstrated
by reorganization of the cytoskeleton, improved morphology and polarity, and enhanced expression of
liver-specific functions (Berthiaume et al., 1996). Within this model, hepatocytes maintained secretion of
hepatic compounds for at least six weeks; a three-fold increase in the secretion window offered by
monolayer collagen gel cultures (Dunn et al., 1991). Another collagen gel sandwich model, combining he-
patocytes with liver sinusoidal endothelial cells (LSEC), mimicked the liver lobular architecture and showed
stable secretion and metabolic activity for up to 4 weeks (Bale et al., 2015). While allowing long-term moni-
toring, the collagen gel sandwich has limitations. Indeed, when compared to 3D spheroids, a PHH-based
collagen gel sandwich does not prevent hepatocyte dedifferentiation, as evidenced by perturbed glycol-
ysis and gluconeogenesis, and shows lower sensitivity to long-term exposure to hepatotoxic compounds in
cytotoxicity studies (Bell et al., 2018). Moreover, the collagen thickness may hinder cell-cell interactions
(Soret et al., 2021). For these reasons, this model is seldom used to investigate NAFLD.
More recently, spheroids and organoids have become the 3D in vitromodels of choice for studying NAFLD
(Soret et al., 2021). Spheroids and organoids differ based on the origin and number of cell types in the
aggregate, the culture environment or the complexity of their structure (Kang et al., 2021). In this review,
we refer to spheroids as 3D structures produced by free-floating, spontaneous self-aggregation of cell lines
in the presence or absence of an ECM that can recapitulate some functional aspects of the liver. In contrast,
we denote organoids as 3D systems obtained by embedding tissue stem cells, progenitor cells or tissue-
resident cells isolated from liver specimens in a scaffold that imposes a liver-like spatial organization,
thereby enabling modeling of the organotypic structure and function (Kang et al., 2021; Gunti et al.,
2021). Figure 3 details how both NAFLD spheroids and organoids can be obtained from different sources.
Spheroid models
Since the first spheroidmodel in the 1970s (Sutherland et al., 1971), multiplemethods have been developed
to establish systems of increasing sophistication. In NAFLD modeling, the most popular method for
spheroid culture is liquid overlay, where cell suspensions are cultured on ultra low-adhesive surface plates
and formation of spheroids can be monitored in real-time (Gunti et al., 2021). Alternative methods for
spheroid assembly have been extensively reviewed in the scientific literature (Kang et al., 2021; Gilazieva
et al., 2020; Ryu et al., 2019).
The simplest hepatic spheroid model consists of a single cell type, usually HepG2 or PHH. It is worth noting
that spheroids support culturing of differentiated PHH for a minimum of 3–4 weeks. Upon treatment with
pathological concentrations of FFA, carbohydrates, cyclosporin A or insulin, hepatic spheroids enabled in-
duction and investigation of steatosis for up to 5 weeks (Damelin et al., 2007; Bell et al., 2016; Kozyra et al.,
2018). Specifically, thesemodels have helped to elucidate the role of hepatocytes in NAFLD (Damelin et al.,
2007; Chong et al., 2020), the mechanism by which IR elicits de novo lipogenesis and lipid accumulation
(Kozyra et al., 2018), the identity of putative molecular targets or the pharmacological action of novel
compounds to ameliorate the disease (Chong et al., 2020; Eilenberger et al., 2020; Bell et al., 2016). Further-
more, the use of PHH in spheroids (Bell et al., 2016; Eilenberger et al., 2020) has shed light on the relevance10 iScience 25, 103549, January 21, 2022
Figure 3. Development protocol for spheroids and organoids
Both models can be obtained from different sources (cyan panel) -immortalized cell lines, embryonic stem cells (ESC),
pluripotent stem cells (PSC), NAFLD murine models or liver from NAFLD patients. Immortalized cell lines and
differentiated ESC/PSC self-aggregate to form spheroids. To induce the NAFLD phenotype, free fatty acids (FFA)
supplementation is required. To form liver organoids, cells from liver specimens are extracted and isolated. Hence, they
are exposed to selected growth factors in presence of a basement matrix. These liver organoids then differentiate into the
specific cell lines and acquire the NAFLD phenotype upon FFA supplementation (light green panel). In addition,
differentiated organoids can also be obtained from ESC/PSC or immortalized cell lines aggregated in liver spheroids.
After dissociation of the aggregates and subsequent cultivation with a basement matrix, the differentiated organoids are
ready to be used for NAFLD studies. The heterogeneity of the disease, its complexity, the self-organization of the cells or




Reviewof inter-individual variations as a determinant of susceptibility to steatosis development and progression
(Dongiovanni et al., 2015). Thus, PHH-based spheroids could provide an ideal platform to demonstrate
the impact of genetics on the variability in drug responses (efficacy and toxicity) among patients; the major
cause of withdrawal of drugs from the market (Sim and Ingelman-Sundberg, 2011).
By co-culturing hepatocytes with NPC, beyond enhancing hepatocyte function in vitro, researchers can
generate liver-like structures that recover the relevant mechanistic steps in NAFLD-NASH evolution (e.g.
inflammation, HSC activation, and fibrogenesis). Hepatoma cell lines have been co-cultured with primary
HSC to define pathways linked to liver steatosis and fibrosis (Salloum et al., 2021; Hurrell et al., 2020). Spe-
cifically, these co-culture systems showed enhanced collagen production, activation of HSC, upregulation
of genes associated with fibrosis progression – such as collagen type I alpha I (COL1A1), TIMP metallopep-
tidase inhibitor 1 (TIMP1) or actin alpha 2 (ACTA2), and induction of pro-inflammatory cytokines. Bell et al.
(2016) also co-cultured PHH-based spheroids with KC, HSC, and biliary cells, and highlighted that the co-
culture systems enable modeling of an inflammatory response, as measured by an increase in IL-6 secre-
tion. Another example of a multicellular spheroid model has been proposed by Kachlishvili et al. (2020).
The researchers combined a hepatocyte cell line with macrophages to study the effect of low-dose
trans-resveratrol on lipid metabolism and pro-inflammatory processes. They showed a decrease in lipid
accumulation due to enhanced poly(ADP-ribose) polymerase (PARP) activity, following treatment with
the compound. As previous studies in monocultures hinted at an environment and cell-type dependent ef-
fect of resveratrol on metabolic pathways (Lan et al., 2017), the study by Kachlishvili et al. (2020) demon-
strated the relevance of 3D spheroids for investigating the mechanism of action of drug candidates.
Spheroid models have further enhanced our understanding of genetic variants linked to NAFLD. In Tanaka
et al. (2021), HepG2-HSC spheroids were used to evaluate the effect of the MBOAT7 variant on inflamma-
tion in NAFLD. Silencing MB0AT7 expression with siRNA, the authors demonstrated a positive correlation
between the presence of the variant and collagen expression, activation of HSC and expression of inflam-
matory and profibrotic cytokines. A similar system proved relevant to investigate themost common genetic
variant in NAFLD patients, PNPLA3 I148M (Pingitore et al., 2019), and study the mechanisms involved in the




Reviewcharacterized by high fat accumulation and collagen production. This 3D model also captured antifibrotic
effects following exposure to the compounds liraglutide and elafibranor. The same model was later
selected as a screening platform for small molecule inhibitors, leading to the identification of momelotinib
as a putative drug against the PNPLA3 I148M variant (Schwartz et al., 2020). PHH spheroids were addition-
ally used to study the effect of the TM6SF2 E167K variant on steatosis establishment and progression
in vitro (Prill et al., 2019). While the mutation led to higher intracellular lipids and upregulation of choles-
terol biosynthesis and de novo lipogenesis, downregulation of genes implicated in NAFLD (e.g., ACADS,
PNPLA2) revealed discrepancies with observed in vivo pathogenic mechanisms. However, the conclusions
drawn from this study are limited by the small sample size exhibiting the TM6SF2 E167K variant (2 out of 5
PHH donors); a common challenge when working with PHH.
Despite their potential for disease modeling and drug efficacy testing, stem cell-basedmodels are still mainly
used in 2D cultures. Holmgren et al. (2020) assembled PSC-derived hepatocytes and HSC in spheroids,
thereby avoiding the nuisance factor of spontaneous HSC activation induced by the stiffness of the ECM in
2D co-cultures (Wells, 2005). Gene expression analysis revealed similarities with PHH in glucose, lipid and
cholesterol metabolism, reinforcing its suitability for NAFLD research. However, limited urea secretion and
downregulation of enzymes involved in phase I and II drug metabolism hindered its use for drug screening
studies.
Notwithstanding their simplicity and low cost, spheroid models offer limited control over their assembly
and size when cultured in standard non-adhesive plates, presenting a scalability and reproducibility issue
for liver spheres. Indeed, clusters of spheroids tend to merge into larger aggregates, challenging cell
viability in culture by hampering both the intake of nutrients and oxygen diffusion (Underhill and Khetani,
2018a). To overcome this drawback, protocols detailing automated assembly of liver spheres have been
published (Meseguer-Ripolles et al., 2021). In addition, novel approaches have incorporated the inclusion
of hydrogel scaffolds, which direct the assembly of spatially isolated, controlled-size spheroids, in the
development protocol (Ryu et al., 2019).Organoid models
Liver organoids are 3D culture models obtained by embedding tissue stem cells, progenitor cells or tissue-resi-
dent cells isolated from liver specimens within a hydrogel ECM. Their development protocol allows tighter
control over the spatial organization of the multicellular aggregate, better approximating the heterogeneity
and organotypic structure observed in vivo (Gunti et al., 2021); once the exposure to growth factors and support
matrices enabling differentiation ofmultiple cell types has been defined. Organoids supersede the ability of 2D
cultures to model (patho)physiological processes, spanning cell differentiation, migration and cell-cell interac-
tions. Furthermore, they retain genomic stability and, owing to wide expansion in culture, are suitable for
long-term storage and high-throughput screening of drugs (Soret et al., 2021).
Murine-derived organoids have been widely used to model the NAFLD phenotype. After feeding wild-type
or genetically modified mice with high-fat containing or specialized diets (such as the methionine and
choline-deficient diet), researchers can harvest liver tissue for cell isolation and culture the cells within a hy-
drogel ECM stimulated with selected stem cell media or growth factors (Broutier et al., 2016). Recently, El-
badawy et al. (2020) modeled NAFLD progression via murine organoids assembled with hepatocytes and
activated HSC isolated from animals at three distinct disease stages (mild, moderate and severe NASH)
(Elbadawy et al., 2020). In doing so, Elbadawy et al. established a model to investigate the effect of genetic
stability and lipid metabolism on NAFLD progression. The authors noticed larger size and enhanced
release of pro-inflammatory cytokines in early stage organoidmodels, compared to later stage ones. Other
murine organoids have been used to decipher liver metabolism and its response to therapeutic com-
pounds. For example, Pittol et al. (2020)explored the dependency of metabolic functions on Farnesoid X
receptor (FXR) isoforms; Sano et al. (2021) elucidated the associations among free amino acids, FFA and
the Keap1-Nrf2 system – involved in the principal protective response to oxidative and electrophilic
stresses (Turpaev, 2013) – in lipotoxic hepatocytes, while Liu et al. (2021) investigated the use of uridine
to ameliorate NAFLD. Despite notable successes, murine-based organoids can only approximate the path-
ophysiology of human NAFLD (Kim et al., 2020), suggesting a human organoid model might provide a




ReviewSeveral approaches for the development of human organoids tomodel NAFLD (and its extra-hepatic organ
involvement) have recently been published. Ouchi et al. (2019) created a model from human PSC by co-
differentiating epithelial and stromal lineages to form spheroids, later embedded in Matrigel and cultured
with retinoic acid and maturation media. This protocol successfully yielded NPC including HSC-like cells,
Kupffer-like cells and biliary stem cells; as well as hepatocyte-like and cholangiocyte-like cells, as confirmed
by single-cell transcriptomics and FACS analysis. Upon FFA exposure, the organoids acquired a NAFLD
phenotype denoted by steatosis, inflammation, hepatocyte ballooning and collagen production; hallmarks
of NASH. Gurevich et al. (2020) opted instead for iPSC-derived cryopreservable hepatocytes sourced from
NASH donors for organoid development. When co-cultured with physiologically-relevant ratios of isogenic
HSC-like and Kupffer-like cells on collagen-coated ultra-low binding plates, the hepatocytes assembled in
organoids amenable to observation for over 10 days. This system, characterized by the formation of bile
canaliculi, proved useful for drug metabolism studies. In alignment with scientific evidence (Teo et al.,
2014), efficient hepatocyte differentiation was promoted via glycogen synthase kinase 3 (GSK3) inhibition,
which is known to induce endoderm differentiation. Similarly to Ouchi et al. (2019), treatment with FFA
induced a dose-dependent accumulation of intracellular lipids and establishment of a NASH phenotype.
McCarron et al. (2021) instead developed bipotent ductal organoids derived from end-stage NASH patient
liver explants, with normal donor livers as controls. Strikingly, NASH patient-derived organoids were highly
diverse in terms of metabolic and pro-inflammatory pathways and response to drugs. Moreover, the model
was characterized by increased sensitivity to apoptosis, increased FFA induced lipid accumulation, and
reduced albumin secretion– all typical features of advanced NASH. Another hepatic organoid model
was developed using posterior foregut and hepatic endoderm. FFA induction elicited increasing lipid per-
oxidation and ROS. Interestingly, this 3D model highlighted disruption of the bile canalicular network with
disease progression (Ramli et al., 2020).
Several organoid models recapitulating NAFLD phenotypes have used bulk RNA sequencing (RNA-seq) to
identify gene signatures and pathways associated with the disease (McCarron et al., 2021; Elbadawy et al.,
2020; Beisner et al., 2021; Ouchi et al., 2019). Yet, only a few have included flow cytometry (Ouchi et al., 2019;
Gurevich et al., 2020; Ramli et al., 2020; Abbey et al., 2020) or single-cell RNA-seq (Ouchi et al., 2019) in their
research to determine the proportion of the different cell types present in these organoids. Quantifying such
ratio might inform protocols offering tighter control over the development of these 3D systems, and help
address two open challenges: heterogeneity and low reproducibility (Garreta et al., 2020).
The organoid technology, especially when based on human stem cells, holds great promise for investi-
gating NAFLD pathophysiology due to the ability to overcome confounding factors introduced by animal
models. Thanks to enhanced stability and complexity, organoid models offer a viable platform for future
drug development pipelines. The establishment of new cryopreservation (Gurevich et al., 2020) and repro-
ducibility (Nuciforo and Heim, 2020) standards will certainly aid in unlocking the potential of organoids to
offer a preclinical alternative to animal models in the near future. Indeed, validated organoids could pro-
vide an easy to image and more accurate model of human NAFLD. Recently, Takebe et al. (2017) targeted
organoids reproducibility by establishing a technological platform to manufacture standardized liver buds
starting from 3 committed progenitors on a large scale (>108).
We note that the bioengineering field is boosting efforts toward controlling organoids’ cellular complexity,
providing vascular networks, and enhancing organoid maturation (Garreta et al., 2020). For example, Guye
et al. (2016) showcased the use of heterologous GATA-binding factor 6 (GATA6) expression to trigger co-
differentiation events within an iPSC population and obtain, within 2 weeks, a complex tissue with liver-like
phenotype. In Velazquez et al. (2021), engineering of gene regulatory networks in PSC-derived human liver
organoids enabled advancement of maturity and vascularization of the obtained in vitro system. In addi-
tion, gene editing using CRISPR/Cas9 has also been used in bioengineering to alter and study the function
of specific genes. For example, Abbey et al. (2020) deleted Tribbles-1 (TRIB1) – a gene associated with
NAFLD, in human iPSC which were then used to create hepatic spheroids.Liver-on-a-chip
Despite having proved informative for the study of NAFLD and complex diseases, a major drawback of the
static 3D cultures is the lack of long-term control over fluid shear stress, nutrient/gas exchange or waste
removal. To enable the automated control of such factors, microfluidic technology and liver-on-a-chip ap-




Reviewthe cost and complexity of microfluidic setups constitutes a barrier to their diffusion in laboratories, the
standardized fabrication of chips favors reproducibility, a hurdle in organoid research.
Several liver-on-a-chip systems have recently been proposed to study NAFLD. The first appearing in the
scientific literature approximated the liver architecture and microvasculature by culturing HepG2 cells in
parallel microchannels mimicking the endothelial barrier (Gori et al., 2016). This microfluidic device demon-
strated the ability of FFA perfusion to recapitulate steatosis. Since then, the combination of multiple cell
typesmade on-chip cultures amenable to the study of cell-cell interactions, better reflecting the complexity
of the hepatic microenvironment. Suurmond et al. (2019) co-cultured HUVEC with GelMa-encapsulated
HepG2 to investigate NAFLD pathogenesis. Similarly to Gori et al., their system, distinguished by high
cell viability and homogeneous cell distribution, enabled monitoring of steatosis establishment. Inclusion
of KC in this in vitro model led to enhanced ROS expression and proinflammatory cytokine release. While
HepG2 are a widely used cell line to investigate regulation of drug-metabolizing enzymes, PHH are the
preferred choice in biotransformation studies, thanks to their in vivo-like functionality (Wilkening et al.,
2003).
In light of their similarities to PHH, researchers increasingly based in vitro models on HepaRG cells. Suur-
mond et al. (2019) highlighted that by substituting HepG2 with HepaRG cells, their liver-on-a-chip dis-
played elevated levels of proinflammatory cytokines and improved reversibility of steatosis. HepaRG, in
conjunction with KC, HUVEC and HSC encapsulated in GelMA, were used in the microfluidic model pro-
posed by Cho et al. (2021). Through a 21-day life-span, the system recapitulated NASH features and
showed neovascularization. Freag et al. (2021) also developed an on-chip model by co-culturing primary
human hepatic cell lines (hepatocytes, KC, HSC and LSEC). In this system, lipotoxic conditions successfully
generated the NASH phenotype, including hepatocellular ballooning. Furthermore, a PHH-based liver-on-
a-chip modeled the progressive intracellular lipid accumulation and reduction in cytochrome P activity
observed in NAFLD patient samples (Kostrzewski et al., 2020). Interestingly, the presence of the PNPLA3
I148M variant in three of the donor samples allowed the authors to highlight that this variant can worsen
the NASH phenotype through effects on HSC.
Despite the numerous advantages of liver-on-a-chip platforms to study NAFLD, the liver is not the only or-
gan involved in the disease, with adipose tissue (Stojsavljevic et al., 2014) and the gut (Scarpellini et al.,
2014) known to play a key role in its progression. For this reason, it is important to study the interactions
between multiple organs, and their contribution to disease establishment and progression. Multi-organ
systems, also known as body-on-a-chip, are emerging as technological platforms to study the efficacy
and safety of drugs (Picollet-D’hahan et al., 2021; Chen et al., 2020; Skardal et al., 2020). As most of the
lipids accumulated in the liver are attributed to dietary intake, Lee and Sung (2018) focused on the gut-liver
axis and developed an on-chip device generating hepatic steatosis. Their gut-liver-on-a-chip device con-
sists of two chambers, incorporating Caco-2 (gut) and HepG2 (liver) cells, separated by a porousmembrane
and a scaffold on the intestinal part. Using this device, Lee and Sung showed that butyrate, a compound
known to enhance the gut barrier function, attenuated lipid accumulation; a benefit not observed when
the drug was tested on hepatocytes alone. Recently, Slaughter et al. (2021) developed a body-on-a-chip
with adipose and liver tissue, to evaluate the mechanisms involved in NAFLD development and serve as
a drug screening platform. The authors were able to validate the indirect influence of adipocytes on hepa-
tocytes in NAFLD progression. At the cost of greater complexity, the examples above hint that body-on-a-
chip devices may offer a better approximation of the in vivo NAFLD environment.3D bio-printed liver-like tissues
Three-dimensional bio-printing is another promising technique for the development of in vitromodels. 3D
structures, including liver-like tissues, are generated via layer-by-layer, spatially controlled deposition of
biological materials, biochemicals and cells (van Grunsven, 2017). A comparative analysis of the three
most established methods to generate 3D bio-printed liver structures (e.g., inkjet-based, extrusion-based,
and photocuring-based bioprinting), is extensively reviewed elsewhere (Murphy and Atala, 2014; Ma et al.,
2020). Despite notable advantages, a challenge to the development and widespread use of 3D bio-printed
structures is the selection of an appropriate bio-ink. Indeed, thematerial must show compatibility with both
cells and the printing process, while retaining physicochemical –and therefore functional– properties anal-
ogous to the organ under consideration. Alginate, gelatin, and collagen are among themost routinely used




ReviewExtensive research has been carried out on bio-printed liver structures (Norona et al., 2016; Smith et al.,
2004; van Grunsven, 2017). To the best of our knowledge, however, only one 3D bio-printed system has
been used to generate the NAFLD phenotype (Kizawa et al., 2017). In this study, a pathological liver tissue
was bio-printed using cells harvested from genetically obese Zucker rats with NAFLD. Specifically, the Ken-
zanmethod (Moldovan et al., 2017) was used to create a scaffold-free bio-printed structure from liver spher-
oids composed of rat hepatocytes and mouse fibroblasts. The authors observed high lipid content over
23 days, suggesting that the pathological conditions could be retained and monitored long-term. Despite
being designed to investigate drug-induced liver injury, the sophistication of the bio-printed structure
proposed by Nguyen et al. (2016) makes it an ideal candidate for the study of NAFLD and NASH. This
two-compartment system includes NPC – HUVEC and HSC – seeded at the boundary of each compart-
ment, filled with PHH.
In parallel, due to the shortage of donor organs and inherent risks, researchers are exploring alternative
solutions to liver transplant in patients with advanced liver diseases. Emerging approaches in development
include liver-like structures bio-printed from HepG2 (Jeon et al., 2017; Ide et al., 2020) or PHH (Kim et al.,
2017, 2018) that could pave the way to artificial livers in the future.
3D bio-printing technology may also enhance the assembly of liver-on-a-chip systems, which present chal-
lenges such as biological culture preparation (Bhatia and Ingber, 2014). The 3D bio-printed organ-on-a-
chip of Lee and Cho (2016) was devised to overcome limitations such as spatial heterogeneity and the
difficulty of providing multiple types of ECM environments when studying cell–ECM interactions (Yeon
and Park, 2007). HepG2 cells encapsulated in collagen type I, and HUVEC encapsulated in gelatin were
used to construct 2D and 3D hydrogel-based on-chip devices. Similarly, Bhise et al. (2016) developed a
liver-on-a-chip with bio-printed HepG2/C3A spheroids. The viability of both models, their extensive life-
span and similarities with intact liver tissue, makes them promising systems for both NAFLD research
and drug screening pipelines.
Taken together, although use in NAFLD research is limited, these studies highlight the potential use of
3D bio-printing. However, to enable more widespread use, the costs and specialized knowledge and
expertise required to establish and maintain this technology will need to be addressed (van Grunsven,
2017).USE OF IN VITRO MODELS IN NAFLD DRUG DEVELOPMENT PIPELINES
The majority of clinical trials have focused on patients with NASH and bridging fibrosis, who have an
increased risk of developing cirrhosis and adverse outcomes. Depending on the drug mechanism of ac-
tion, the primary endpoint of interventional trials comprises either NASH resolution without worsening of
fibrosis or a minimum of one-stage fibrosis improvement without worsening of NASH. Yet, most clinical
trials have been unsuccessful and 4 out of 5 NASH treatments reaching phase III were recently termi-
nated. This suggests monotherapies –individual drugs– might be insufficient to tackle the complex inter-
action between metabolic, inflammatory and fibrotic pathways that characterize this disease. As a result,
evaluation of drug combinations is becoming a major focus of Pharma NASH pipelines. However,
despite more than twenty years of intense research activity, no breakthrough has occurred. Indeed,
the phase II ATLAS study (NCT03449446) failed to meet the primary endpoint, except for the firsoco-
stat-cilofexor combination, currently subject of further investigation (Gilead Sciences, 2019). While a
detailed discussion of the pharmaceutical compounds that have been part of clinical trials does not
fall under the scope of this review, we point to extensive recent reviews that address this topic (Fallow-
field et al., 2021; Campbell et al., 2021; Guirguis et al., 2021). In order to facilitate the reader’s under-
standing of this section, we have provided two tables that summarize the most relevant information of
the ongoing (Table 2) and the terminated/completed (Table 3) phase III clinical trials for pharmaceutical
compounds in NAFLD.
In vitro cell culture assays have been used to support pre-clinical development of candidate therapies and
to validate the utility of new cellular models. For instance, obeticholic acid (OCA) has been tested in human
iPSC-derived hepatocytes (Parafati et al., 2018), a co-culture of human hepatoma cells (Huh7) and HSC
(LX-2) (Anfuso et al., 2020) and an organotypic human hepatocyte system (Dash et al., 2017). Boeckmans
et al. (2020) investigated the properties of several PPAR agonists in PHH, HepaRG, HepG2, LX-2 and human
skin stem cell-derived hepatic cells. Other studies, include the use of human HSC (HSC-T6 and LX-2) toiScience 25, 103549, January 21, 2022 15
Table 2. Ongoing phase III clinical trials in NAFLD and NASH
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Table 3. Terminated and completed phase III clinical trials in NAFLD and NASH
Compound/
Company or
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Reviewdetermine the efficacy of selonsertib in liver fibrosis (Yoon et al., 2020) or primary rat HSC to evaluate the
effects of pioglitazone in vitro (Kawaguchi et al., 2004).
Additionally, fibrogenic spheroids have been used to test the efficacy of putative drugs (e.g., sorafenib (Ro-
mualdo et al., 2021), lanifibranor, elafibranor, or cenicriviroc (Hurrell et al., 2020)) in mediating resolution of
NASH, thereby validating the role of spheroids for drug screening.
Beyond being suitable models to elucidate NAFLD pathogenesis, liver-on-a-chip systems also play a key
role in drug development. To date, Gori et al. (2016), Freag et al. (2021), Cho et al. (2021), Du et al.
(2021) and Gori et al. (2021) have used liver-on-a-chip devices to test the ability of polyphenols, OCA, ela-
fibranor, and pirfenidone to ameliorate NAFLD. Interestingly, while the disease-modifying effects of elafi-
branor were shown in a liver-on-a-chip assay, this did not translate to clinical efficacy in a pivotal phase III
NASH trial. As a consequence, the drug program was recently terminated (GENFIT, 2020). These contrast-
ing in vitro versus in vivo observations indicate that preclinical NAFLD models still have a long way to go
before reliably simulating human NAFLD and predicting patient responses to therapies.TRANSLATION OF IN VITRO PLATFORMS
The challenge of identifying an efficacious treatment for the disease is evidenced by the litany of recent
clinical trial failures that have encompassed a diverse range of targets. Notwithstanding, many synthetic
drugs are currently in development as monotherapy or combination therapy regimens. The availability
of reliable human-based in vitro models would help to address this challenge, by both enhancing our un-
derstanding of NAFLD progression and predicting the therapeutic response to drug candidates. So far,
in vitro models have only managed to recapitulate specific aspects of the in vivo disease phenotype.
Indeed, the establishment of multi-dimensional systems that reflect the combined effects of genetics,
sex, comorbidities and inter-organ cross-talk remains a pipe dream. Mounting evidence suggests, howev-
er, that the complexity of in vitro models will be key to screen drugs and to predict clinically relevant ther-
apeutic responses. This is illustrated in Lee and Sung (2018), where the beneficial effect of butyrate on lipid
accumulation only became apparent in a gut-liver-on-chip, but was not detected when the compound was
tested using hepatocytes alone.
An ideal NAFLD in vitro model used for drug screening should satisfy biological fidelity and usability re-
quirements. Biological fidelity depends on the selection of appropriate liver cells (parenchymal cells and
NPC) and their aggregation in a structure enabling cell-cell and cell-ECM interactions. Future trends will
likely see a transition from immortalized cell lines to PSC, due to their almost unlimited supply, life-span
and similarity to in vivo human phenotype (Hay et al., 2007; Gao and Liu, 2017). For the observed response
to be shaped by inter-organ cross-talk, these systems need to be linked with intestinal, pancreatic and ad-
ipose tissue models. 3D liver structures cultured in perfusion devices are quickly developing to meet these
standards. Usability of such models relies instead on their lifetime (e.g., a minimum of 2–3 weeks of obser-
vation are needed for cytotoxicity testing) and the availability of specialized know-how for their operation.
To ensure clinical relevance, NAFLD in vitromodels require validation against known features of in vivo hu-
man pathogenic processes or responses to therapeutic agents. Such validation could be performed via an
‘omics’ approach, which can evaluate the degree of pathological equivalence between an in vitro model
and human liver samples at the molecular level, as measured by differentially expressed genes and en-
riched pathways. Such a strategy has been adopted by Ramli et al. (2020) and Feaver et al. (2016).
Alternatively, models could be assessed by their ability to reproduce results obtained in ongoing clinical
trials. For example, Hurrell et al. (2020) demonstrated the potential of their system as a drug screening plat-
form by testing pharmaceuticals that were in phase II or phase III clinical development. However, robust
human validation and critical comparative analyses are rarely performed, with most researchers focusing
on specific genes and pathways of interest (e.g., the expression level of TGF-a, a-SMA or TNF-b eliciting
fibrosis and inflammation) when designing in vitro systems for NAFLD. Ideally, extensively validated plat-
forms would allowmore reliable pharmacodynamic-pharmacokinetic and toxicity assays of candidate com-
pounds for NAFLD treatment, de-risking subsequent clinical trials. Several drugs that are currently in phase
III have undergone preliminary in vitro testing. For instance, Aramchol was tested in bioassays on PHH,
HSC, and pHSC (Fernández-Ramos et al., 2020; Bhattacharya et al., 2021). While not using 3D in vitro
models, the authors selected multiple cell lines to investigate genes and pathways modulated by AramcholiScience 25, 103549, January 21, 2022 21
Figure 4. Potential applications of in vitro models in translational research for NAFLD
The combination of ‘omics’ and cell cultures has the potential to enable the study NAFLD patients ‘in-the-dish’, resulting
in the design of effective treatment or identification of predictive and prognostic biomarkers. In vitro NAFLD models,
combined with metabolomic and genomic analyses/genetic variant studies, permit the identification of pharmacological
targets and susceptible patient subpopulations. Once a putative drug – or combination of drugs – has been indicated as a
candidate NAFLD therapy, several pharmacological investigations test the efficacy, cytotoxicity, and possible
interactions between compounds. Drugs that are successfully triaged are funneled to clinical evaluation. The ultimate





Review(e.g., downregulation of SCD1, COL1A1, and ACTA2; upregulation of PPARG). This cost-effective strategy
benchmarks a putative drug according to multiple aspects of NAFLD, before proceeding to test its efficacy
in suitable cohorts of patients. Similarly, in vitro studies with OCA in co-cultures of Huh7 and HSC (Anfuso
et al., 2020) or PHH collagen gel sandwich (Dash et al., 2017), have delineated mechanisms of action
including modulation of collagen and MMP2 and 9 activity, as well as its possible toxicological effects. Fig-
ure 4 shows the different potential applications of in vitro models in translational research for NAFLD.
Despite the advantages they offer, 3D in vitro models remain expensive and inaccessible to new users.
Indeed, liver-on-a-chip and bio-printed liver-like tissues are quite complex and steep learning curves are
associated with their operation. Ideally, technological advancements and the establishment of rigorous
standards will enable these models to become a concrete alternative to animal models in the near future.
FUTURE PERSPECTIVES
Emerging in vitro human-based models have enhanced our understanding of NAFLD evolution and dis-
ease mechanisms. However, open challenges remain. Among these, the most prominent are the ability
of the model to encompass the whole spectrum of the disease, to reproduce the inter-individual variability
observed in NAFLD patients and capture the interaction between multiple organs involved in the patho-
genesis of the disease. We expect that in the near future complex in vitro models, such as body-on-a-
chip based on iPSC or PHH, will become the platform of choice to mimic NAFLD establishment and
progression. Inclusion of physiologically-based toxicokinetic computer modeling to study ADME (absorp-
tion, distribution, metabolism, and excretion) in these systems will likely represent a further step toward the
replication of the human liver microenvironment.
The availability of validated preclinical models will streamline the adoption of a quantitative approach to (a)
the identification of NAFLD etiology and potential therapeutic targets, and (b) the rational design of phar-
macological treatments. These aims are increasingly pursued in a biological systems control perspective,
wherein a disease arises due to failure of multi-scale control mechanisms ensuring robustness of biological
processes to internal/environmental perturbations. Using this approach, mathematical models and gene
regulatory networks reconstructed from ‘omics’ data provide new insights on the establishment of dis-




Reviewproblem. For example, Liao et al. (2020) used a kinetic model of hepatic fructose metabolism to simulate
the effect of excessive dietary uptake of this sugar on dyslipidemia observed in early NAFLD patients. The
authors identified fructokinase as a molecular target of the fructose pathway and predicted its suppression
would revert lipid accumulation. Van Riel et al. (2020) used instead a machine learning algorithm, informed
by metabolomic and transcriptomic time-series, to predict the metabolic response induced by treatment
with a Liver X Receptor (LXR) agonist. Currently, 3D models are mainly used for biological studies due to
their cost and low-throughput. Tackling such limitations will prompt adoption of these in vitro models
by the pharmaceutical industry. Indeed, within drug development pipelines, these models would allow
only the most promising compounds to funnel toward clinical trials, with obvious economic benefit. If
used in combination with disease-relevant ex vivo models (e.g., human precision-cut liver slices) (Palma
et al., 2019), in vitro models might help to reduce the (over)reliance on in vivo models for drug efficacy
and toxicological studies.
We expect complex in vitro platforms to be increasingly integrated with ‘big data’ for compound testing,
identification of therapeutic targets, and personalized medicine applications. Precision medicine ap-
proaches would enable, first, the clustering of NAFLD patients by disease stage and/or genetic variants
(e.g., PNPLA3) and the development of in vitromodels from patient-derived iPSC on which to assess safety
and efficacy of candidate therapies. Second, these studies could identify novel companion biomarkers of
NAFLD progression or regression, thereby supporting the design of non-invasive diagnostic tests.
In conclusion, we have provided a comprehensive overview of various in vitromodels proposed to study the
pathophysiology of NAFLD. The different models available for this disease have specific advantages and
disadvantages. Accordingly, the choice of model may depend on the particular context of use.
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